Shawbrook Group has disclosed the price range for its forthcoming initial public offering (IPO), aiming for a market capitalisation of £1.8bn ($2.4bn) to £2bn ($2.7bn) upon admission to the London Stock Exchange.
The financial institution, which had previously declared its intentions to go public this month, is expected to finalise its admission on 4 November 2025, with shares priced between 350p and 390p.
The current sole shareholder of the company, Marlin Bidco, is expected to offload between 79.9 million and 81.1 million shares.
Concurrently, Shawbrook Group intends to issue between 12.8 million and 14.3 million new shares to secure £50m in gross proceeds.
Additionally, an over-allotment option could result in the sale of up to 14.1 million more existing shares.
Following the IPO, the public is projected to own approximately 18% of Shawbrook Group’s shares if the over-allotment option is not executed, increasing to around 21% if the option is fully exercised, not accounting for treasury shares.
The offering will be available to qualified institutional buyers in the US and UK-based retail investors.
The retail portion of the offer is anticipated to stipulate an application sum of at least £250.
The final deadline for retail offer applications is scheduled on 29 October 2025.
Shawbrook has appointed Ardea Partners International as its financial adviser for the IPO while Goldman Sachs International will act as the sponsor, joint global coordinator, and joint bookrunner.
Barclays Bank is also a joint global coordinator and joint bookrunner, with Stifel Nicolaus Europe, Deutsche Bank AG London Branch, and UBS serving as joint bookrunners.
“Shawbrook targets £2bn of market capitalisation in IPO” was originally created and published by Leasing Life, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
